Xcelerate Inc. has formally transitioned its AfiyaSasa Africa initiative from planning to implementation with new partnerships in Tanzania. The company announced on May 4, 2026, that its majority-owned subsidiary, AfiyaSasa Africa LLC, has engaged Dr. Desire Ruhinda, a prominent Tanzanian medical professional, in a consulting capacity. This collaboration aims to assess and enhance artificial intelligence-driven healthcare delivery models in underserved regions.
As part of the new agreement, Dr. Ruhinda will play a pivotal role in reviewing the AdviNOW Medical system and determining the localization requirements needed to align with Tanzanian healthcare guidelines. His expertise will also aid in identifying clinical sites for a pilot program, which seeks to establish proof of concept for the initiative.
In conjunction with Dr. Ruhinda's efforts, Dr. Anja Glisovic, the Chief Science Officer of Xcelerate, is scheduled to lead an on-site research and development engagement in May. Dr. Glisovic's visit is expected to refine the company's intellectual property strategies and advance discussions surrounding high-growth medical technologies.
Xcelerate’s management is optimistic that this evaluation phase will yield critical insights into the operational feasibility and cost structure of introducing AI-supported healthcare systems in emerging markets. By leveraging local expertise in Tanzania, the company aims to ensure its healthcare technologies are effectively adapted to meet regional needs.
Dr. Desire Ruhinda brings significant experience in healthcare delivery to the project, having co-founded a hybrid healthcare model in Tanzania that served over 15,000 patients. His contributions focus on integrating AI capabilities into accessible solutions aimed at improving patient outcomes and healthcare delivery.
Xcelerate has entered into a consulting agreement with Dr. Desire Ruhinda to progress the AfiyaSasa Africa initiative, transitioning from strategic planning to operational execution. This is a significant step towards evaluating AI-enabled healthcare solutions in underserved markets.
The plan involves assessing the capabilities of the AdviNOW Medical system and identifying localization needs while compiling clinical data to align with local treatment guidelines. This comprehensive approach aims to ensure that the future pilot programme is tailored for the Tanzanian healthcare environment.
Dr. Anja Glisovic, as the Chief Science Officer, will visit Tanzania to lead R&D discussions, refine intellectual property strategies and support the evaluation of innovative medical technologies. Her expertise is expected to enhance the company's alignment with its strategic goals and growth opportunities.
The management anticipates that completing the evaluation phase will procure critical insights into the feasibility and operational framework required for deploying AI-enhanced healthcare systems. This could result in improved healthcare access and patient outcomes in emerging markets.
Dr. Ruhinda's regional expertise and experience in healthcare delivery make him an invaluable asset to the initiative. His background will help tailor healthcare technologies to meet the unique challenges of the Tanzanian market.
By adapting advanced technology like AI-driven models to local requirements, Xcelerate aims to improve healthcare service delivery, enhance patient coordination and ultimately lead to better health outcomes in Tanzania.
Xcelerate's strategy includes not only developing innovative healthcare technologies but also harnessing a portfolio of medical patents and licenses. This dual approach aims to create a sustainable impact in the medical sector, particularly in emerging markets.
Investors should note that forward-looking statements involve inherent risks and uncertainties, which may affect the actual performance of the company. While the company is optimistic about its plans, actual results might differ from projections.